TNFRSF10A and colonic neoplasm: A recent study reported that the orally available tyrosine kinase inhibitor BAY61-3606 sensitized colon cancer cells to TRAIL-induced apoptosis through the upregulation of DR4 in a p53-dependent mechanism [52].